Like a Good Wine, MS DMT efficacy takes time

L

Determinants of therapeutic lag in multiple sclerosis. Roos I et al. Mult Scler 2021 PubMedhttps://doi.org/10.1177/1352458520981300

Article information 

A good wine takes time……and you accept this but this is also true for MS disease modifying treatments. ProfG brought the idea of the length dependent axonopathy (Long nerve tracks take on damage more quickly) and therapeutic lag (it takes time to see benefit) into being and now can come up with a term for the time window for prevention. So how long does it take for therapy to show benefit. In this study from Australia by Dr Roos….(no I didn’t make it up. Shame there wasn’t a Dr Kanga:-) in the female group it took 4months and in males it took 7 months. I predict that in progressive disease this takes a few years. So if you start taking a treatment and notice worsening it doesn’t mean it is not working. This is also a reason why in trials they rebaseline say the MRI outcomes to about 6 months

Background:

A delayed onset of treatment effect, termed therapeutic lag, may influence the assessment of treatment response in some patient subgroups.

Objectives:

The objective of this study is to explore the associations of patient and disease characteristics with therapeutic lag on relapses and disability accumulation.

Methods:

Data from MSBase, a multinational multiple sclerosis (MS) registry, and OFSEP, the French MS registry, were used. Patients diagnosed with MS, minimum 1 year of exposure to MS treatment and 3 years of pre-treatment follow-up, were included in the analysis. Studied outcomes were incidence of relapses and disability accumulation. Therapeutic lag was calculated using an objective, validated method in subgroups stratified by patient and disease characteristics. Therapeutic lag under specific circumstances was then estimated in subgroups defined by combinations of clinical and demographic determinants.

Results:

High baseline disability scores, annualised relapse rate (ARR) ⩾ 1 and male sex were associated with longer therapeutic lag on disability progression in sufficiently populated groups: females with expanded disability status scale (EDSS) < 6 and ARR < 1 had mean lag of 26.6 weeks (95% CI = 18.2–34.9), males with EDSS < 6 and ARR < 1 31.0 weeks (95% CI = 25.3–36.8), females with EDSS < 6 and ARR ⩾ 1 44.8 weeks (95% CI = 24.5–65.1), and females with EDSS ⩾ 6 and ARR < 1 54.3 weeks (95% CI = 47.2–61.5).

Conclusions:

Pre-treatment EDSS and ARR are the most important determinants of therapeutic lag.Keywords

About the author

MouseDoctor

3 comments

Leave a Reply to luis fernando Cancel reply

  • I remember asking my neurologist at a key West London Hospital about therapeutic lag having read about it on here and he does not believe in it.
    The fact I felt unwell for the following year he attributed to the fact that alemtuzumab had not worked rather than on the fact that I was unwell before taking the alemtuzumab and then had to contend with alemtuzumab induced menopause symptoms

    • Some neurologists think the world is flat….I have seen the prescriptions from some West London Hospitals….and it appears that some people just don’t read and assimilate:=(

  • This time frame almost match normal immune responses
    Also the fact the women immune resposes are generally faster and stronger than men

By MouseDoctor

Translate

Categories

Recent Posts

Recent Comments

Archives